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Abstract 
 
C. parapsilosis may be responsible for bloodstream infections (BSI) and it is characterized by an 
increased incidence of fluconazole resistance. A 75-year old woman with severe comorbidities 
received the insertion of a peripherally-inserted central venous catheter. Fluconazole did not prevent 
a C. parapsilosis BSI hence caspofungin was started after a nephrotoxic first-line treatment with 
amphotericin B. The ratio of peak plasma concentration over the minimum inhibitory concentration 
(Cmax/MIC) ratio was adopted to maximize efficacy of caspofungin. MIC and plasma Cmax values 
were obtained by broth microdilution and LC-MS, respectively. Interestingly, daily doses of 1 
mg/kg (total daily dose, 50 mg) allowed the achievement of Cmax/MIC values >10. The optimized 
regimen was safe and effective, leading to negative blood culture at day 8. The patient was 
discharge at home at day 21. Therefore, individualized dosing regimens of caspofungin may be 
effective and safe even in the case of C. parapsilosis BSI. 
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Introduction 
 
C. parapsilosis is the second or third most common Candida species isolated from bloodstream 
infections (BSI) worldwide [1, 2].  Although fluconazole is generally effective in infections caused 
by this Candida spp., an increasing incidence of fluconazole resistance has been lately documented 
among clinical isolates of C. parapsilosis [3]. Caspofungin has potent antifungal activity and it has 
been shown to be as effective as, and less toxic than amphotericin B in the treatment of invasive 
candidiasis [4, 5]. Interestingly, minimum inhibitory concentration (MIC) values of the 
echinocandin for C. parapsilosis are higher than those for other Candida spp. due to 
polymorphisms of genes encoding for beta-glucan synthase (i.e., FKS1 and FKS2) [6, 7]. The 
reduced susceptibility of C. parapsilosis for echinocandin was not associated with an increased 
incidence of treatment failure in clinical practice [8], even if some studies reported a relationship 
between the clinical failure of echinocandins and higher MIC values [9]. Additional dose-
fractionation studies showed that the in vivo fungicidal activity of echinocandins is maximized 
against C. albicans isolates when the ratio of maximum plasma drug concentration to MIC 
(Cmax/MIC) approaches 10 [10]. Nevertheless, there are insufficient data to support a correlation 
between echinocandin susceptibility testing and clinical outcome, while antibiogram results may 
widely differ among laboratories.  
Overall, these data (i.e., high prevalence of C. parapsilosis, its natural reduced susceptibility to 
echinocandins, and higher rate of fluconazole resistance) would make infections due to this species 
difficult to manage. 
In the present paper, we describe the case report of a woman with a blood stream infection due to C. 
parapsiolosis and its effective treatment with caspofungin. Of note, drug dosage was optimized by 
the application of a therapeutic drug monitoring protocol. 
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Case presentation 
The case report concerns a 75-year-old female patient, whose medical history was significant for 
systemic sclerosis with diffuse vasculopathy, pulmonary hypertension, gastrointestinal disorders 
(i.e.: recurrent diarrhoea), joints and macro-vascular involvement, mitral and tricuspid 
valvulopathy, chronic renal failure, and hypogammaglobulinaemia. She was diagnosed a candida 
oesophagitis and treated with oral fluconazole for almost 3 months (daily dose of 100 mg; total dose 
of 9 g). The occurrence of dysphagia required the parenteral nutrition through a peripherally-
inserted central venous catheter (PICC). Other pharmacological therapies consisted of daily 
methylprednisolone and immunoglobulins on a monthly basis. Three months later, the patient was 
admitted to emergency department because of onset of fever, dysphagia and worsening dyspnoea. 
Laboratory analyses revealed leukocytosis (12320 cells/mm³, neutrophils 84%) and increased 
procalcitonin (27.81 ng/ml), while chest X-ray showed the presence of right basal pneumonia. The 
patient was treated with non-invasive mechanical ventilation with continuous positive airway 
pressure and subsequently admitted to an Internal Medical ward. Sputum, urine and blood samples 
were taken for microbiological analyses, therapy with piperacillin/tazobactam was started, while 
fluconazole 200 mg/day was continued. 
Blood cultures were performed by the BACTEC 860 system (Becton–Dickinson, Inc., Sparks, MD), 
while the specie was identified using API ID 32C system (bioMerieux, Marcy l’Etoile, France). 
MIC values were determined by Sensititre YeastOne (Thermoscientific), according to Clinical & 
Laboratory Standards Institute (CLSI) clinical breakpoints cut-off values for susceptibility. 
Furthermore, actual values of MICs and minimal fungicidal concentration (MFC) for caspofungin 
were determined by a broth microdilution method in accordance with CLSI document M27-A3 
[11]. Briefly, plates were incubated at 35 °C for 24 h and readings were performed visually. 
Caspofungin MICs were considered as the lowest concentrations of the antifungal agent at which 
well turbidity was 50% of controls or less. After MIC readings, the plates were centrifuged at 2000 
rpm, the supernatant was discarded, and each well was added with 50 µL of sterile saline solution. 
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The saline solution of those wells whose caspofungin concentration was higher than the MIC value 
was transferred in duplicate onto a 150-mm Sabouraud dextrose agar plate and incubated at 35 °C 
for 24 h. MFC value was defined as the lowest drug concentration associated with a killing >99% 
and each test was run in quadruplicate. Antifungal susceptibility testing was performed as described 
above, with and without 50% human serum (obtained from healthy volunteers) in the medium. 
Cultures of blood samples taken the day after the admission confirmed a BSI caused by C. 
parapsilosis (first from PICC than from peripheral vein). Liposomal amphotericin B (3 mg/Kg once 
daily) did substitute fluconazole, and the PICC was removed from the vein without evidence of 
septic thrombophlebitis. Subsequent in vitro susceptibility results yielded the following MIC 
values: flucytosine 0.06 mg/L, amphotericin B 0.25 mg/L, anidulafungin 1 mg/L, caspofungin 0.5 
mg/L, micafungin 0.5 mg/L, itraconazole 0.5 mg/L, voriconazole 2 mg/L, and fluconazole 32 mg/L.  
Both fundus examination and echocardiography were negative, while white blood cell count, C-
reactive protein, and procalcitonin normalized despite the presence of fever. However, a progressive 
worsening of renal function (creatinine increase, from 1.15 g/dL to 2.8 g/dL) occurred the fifth day 
after the hospitalization, so that caspofungin represented the drug of choice. In order to achieve a 
maximum plasma concentration (Cmax)/MIC value ≥10 [10], caspofungin loading and maintenance 
doses were 70 mg and 50 mg/day (as 1 mg/kg/day), respectively. Therapeutic drug monitoring 
started on the third day; caspofungin plasma concentrations were measured 1 h after the dose (Cmax) 
and 1 h immediately before the next administration (minimum plasma concentration, Cmin). The 
measurement of caspofungin plasma concentrations was performed by a liquid chromatography-
mass spectrometry instrument (Waters TQD, Waters, Milford, MA, USA) using a commercially 
available kit (Chromsystems GmbH, Munich, Germany). The plasma Cmax and Cmin values 
accounted for 13.9 and 3.0 mg/L, respectively, and Table 1 reports caspofungin susceptibility 
results obtained by broth microdilution method in quadruplicate. Geometric mean values of MIC 
and MCF for the isolate #11236 were 0.06 and 1.0 mg/L, respectively, showing that Cmax/MIC ratio 
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was 231.6. Interestingly, caspofungin susceptibility significantly decreased for both isolates in the 
presence of 50% of serum in the test medium (4-fold and 2-fold increase in MIC and MCF values, 
respectively; Table 1). Moreover, the Cmax/MIC ratio decreased up to 12.7 in the presence of serum, 
but that value was greater than the pharmacokinetic/pharmacodynamic (PK/PD) threshold [10], 
suggesting that the administration of the chosen maintenance dose could result in an effective 
treatment. In the same in vitro conditions, the Cmax/MFC ratio decreased from 13.9 up to 6.0 (Table 
1). 
The blood culture yielded a negative result on day 8th of caspofungin administration. The patient 
fully recovered after two additional weeks of therapy, and she finally left the hospital. 
Although our data are based only on a case of BSI due to a C. parapsilosis highly susceptible to 
caspofungin in vitro, we confirmed that a good PK/PD ratio was related to a positive outcome of the 
infection. It’s interesting to note that even when the fungicidal parameter was considered and the 
PK/PD ratio decreased (i.e., Cmax/MFC equal to 13.9 or 6.0 without or with serum, respectively), 
the magnitude was still near the optimal achievable effect (i.e.: greater than 10). Finally, 
caspofungin susceptibility testing performed by the commercial system yielded MIC higher than 
those obtained by the reference broth microdilution method (0.5 vs 0.06 mg/L) while it was similar 
to the MFC obtained by the same method (1.0 mg/L). 
 
Discussion 
Fluconazole resistance among C.parapsilosis isolates is not yet a rare event and appears to be 
increasing wordwide [3]. Pfaller et al. showed that  isolates of C. parapsilosis isolates from 
nosocomial and community onset BSI (5.8% and 6.6%, respectively) were resistant to fluconazole 
[12]. Therefore, guidelines suggest to consider antifungals other than fluconazole as therapy for 
invasive candidiasis in patients who have had prior azole exposure and who are unstable or infected 
with species known to have reduced susceptibilities to fluconazole [13]. 
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After a long-lasting exposure to fluconazole, the present patient developed a fluconazole-resistant 
isolate that initially responded to amphotericin B. However, the macrolide administration caused 
the early onset of a renal toxicity. Caspofungin was an effective alternative to amphotericin B, 
because the daily dose was chosen according to target values of PK/PD parameters. Caspofungin 
displays a concentration-dependent activity [14], and both free area-under-the-time-concentration 
curve (fAUC)/MIC and Cmax/MIC ratios are predictive parameters of drug efficacy [14-16]. In 
particular, Cmax/MIC values higher than 4 could predict an improved clinical outcome [17]. 
Therefore, the evaluation of strain sensitivity coupled with therapeutic drug monitoring allows the 
development of dosing strategies that could optimize treatment outcomes for antimicrobial drugs, as 
the present case has demonstrated. 
 
Conclusions 
In conclusion, caspofungin was an effective option to amfotericin B halted for its nephrotoxic 
effects, while the once-daily administration of echinocandins ensures the highest plasma peak 
concentrations. However, the application of PK/PD parameters for the optimization of antifungal 
therapies is still poorly utilised despite their usefulness. Finally, the fungicidal activity of 
caspofungin in the presence or not of serum might be useful information for the clinicians who treat 
life-threatening candidemia, especially in frail patients. 
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Table 1. Caspofungin susceptibilities of the C. parapsilosis isolate #11236 tested by a broth 
microdilution method. 
 
Testing Culture medium Culture medium plus serum 
MIC* (mg/L) 0.06 (0.06-0.06) 1.1 (1.0 – 2.0) 
MFC* (mg/L) 1.0 (1.0-1.0) 2.3 (2.0 – 4.0) 
Cmax/MIC ratio 231.6 12.7 
Cmax/MFC ratio 13.9 6.04 
 
Notes: *, results are expressed as geometric mean (range). 
Abbreviations: MIC, minimum inhibitory concentration; MFC, minimum fungicidal concentration; 
Cmax, maximum plasma concentration. 
 
 
 
 
	
	
